Genzyme Corporation’s Lemtrada Approved In Argentina For Treatment Of Multiple Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

Help employers find you! Check out all the jobs and post your resume.